Domus tests will be among the first to meet the standards required for broad adoption in every global market.
Under $5 to manufacture, offered at cost to nations in critical need
Intuitive and easy to use, across languages,
education levels, and disabilities
As accurate as a
laboratory PCR test:
>95% sensitivity and
Results in 30 minutes or less
Testing for All
Developing the first ever zero-power at-home molecular testing platform, affordable for any household.
Domus Diagnostics is the only company combining cutting-edge custom chemistry with simple manufacturing technology in order to bring low-cost, high accuracy tests for infectious diseases everywhere they're needed.
The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program awards Domus a multi-million dollar grant.
The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), selected Domus Diagnostics earlier this year from among hundreds of applicants to participate in their High-Performance COVID-19 Rapid Tests Fast-Track Program, to accelerate the development of their ultra-low-cost nucleic acid at-home test.